Piper Sandler Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $70
PROCEPT BioRobotics Analyst Ratings
Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT)
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Buy Rating on PROCEPT BioRobotics: Attractive Entry Point Amidst Growth Potential and Upcoming Clinical Catalysts
Jefferies Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating, Maintains Target Price $77
Wells Fargo Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $105
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $77 to $105
Wells Fargo Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
Resilient Growth and Profitability Path: PROCEPT BioRobotics Receives Buy Rating Amid Challenges
Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $95
PROCEPT BioRobotics Analyst Ratings
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $85 to $100
Strong Growth and Strategic Expansion Drive Buy Rating for PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) Receives a Buy From William Blair
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating